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EVALUATING THE GUT-BRAIN AXIS OF PARKINSON’S DISEASE 
PATHOGENESIS AND EXPLORING POTENTIAL THERAPIES 
 
MICHAEL GROOT 
 
ABSTRACT 
 Parkinson’s Disease is a neurodegenerative illness of the central nervous system 
that impacts both cognitive and motor functioning. Current understanding dictates that 
these symptoms are caused by the death of dopaminergic neurons within the substantia 
nigra pars compacta of the basal ganglia. This neuronal death explains part of the 
symptoms, but large clumps of insoluble protein called Lewy Bodies are thought to also 
contribute. The α-synuclein (α-SN) protein is a major component of Lewy Bodies and has 
long been demonstrated to misfold and become aggregated. Classically, these Lewy Bodies 
first appear within the brainstem and spread upwards towards the cortex as the pathology 
progresses. While there have been some suggestions, the mechanism whereby α-SN 
misfolds in the brainstem is not currently understood. Additionally, the interplay between 
Lewy Bodies and dopaminergic neuronal death has not yet been discovered. 
One of the leading theories of α-SN misfolding is related to the gut-brain axis. Our 
gastrointestinal tract is innervated by the enteric nervous system, which sends signals to 
the brainstem via the vagus nerve. Curiously, α-SN is expressed within enteroendocrine 
cells of the intestine. These cells have connections to nerve fibers of the enteric nervous 
system at their basal lamina. The hypothesis reasons that some pathogenic agent can gain 
  vii 
access to the cells of the intestine, cause α-SN to misfold, and cause this damaged protein 
to be transported within the vagus nerve. As the vagus nerve ultimately connects to the 
brainstem, this is where the Lewy Bodies are deposited to initiate Parkinson’s disease. 
Research has investigated this connection thoroughly but has yet to determine 
definitively if this gut-brain axis is truly causing pathology within the brainstem. This 
thesis attempts to provide an overview of the current literature relating to Parkinson’s 
disease as well as the current knowledge of the gut-brain axis. Then, this will evaluate the 
various entities proposed to be the unknown pathogen of the gut-brain axis and discuss 
some of the controversies in the literature. Finally, this thesis will discuss the therapies that 
have arisen from the concept of the gut-brain axis and the potential further directions that 
these therapies imply for research.  
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I. INTRODUCTION 
 This thesis will begin with an overview of Parkinson’s Disease (PD) including its 
history, the cognitive and motor symptoms, and the current knowledge of its pathogenesis. 
Then, it will introduce the gut-brain axis as one of the proposed mechanisms of Parkinson’s 
development and discuss the pathogenic substances that could be causing pathology to 
initiate within the gut. Finally, this will attempt to resolve some of the current controversies 
in the literature and point towards some of the potential frontline therapies that could 
prevent or reverse Parkinson’s disease. 
A. Background and Symptoms 
Parkinson’s disease is a neurodegenerative disease that will affect 930,000 
Americans by 2020 and over 1.2 million by 2030.1 While there are cases of young PD 
diagnoses, the incidence increases drastically in patients beyond 60-years of age.2 It also 
demonstrates a gender-dependent pattern of development. The incidence rate in males is 
19.0 cases per 100,000 people, while females only represent 9.9 cases per 100,000 people.2 
Consistent with this trend, females are on average 2.1 years older than their male 
counterparts at the age of diagnosis.3 
PD is a neurodegenerative disease that is characterized by both motor and cognitive 
symptoms. However, the motor symptoms of PD are generally the symptoms that appear 
first, and are characterized by the acronym TRAP: Tremor at rest, Rigidity, Akinesia, 
Postural instability.4 Several different types of tremors can be present in PD patients, but 
tremors while at rest are the most common.5 Further, akinesia is classified as a difficulty in 
initiating movement, while Bradykinesia is classified as slowness of movement.5 
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Furthermore, many patients experience postural instability and gait difficulty whereby it 
becomes difficult to raise the feet off the ground, resulting in a shuffling gait when 
walking.5 
While the motor symptoms can often be the most outwardly debilitating, non-motor 
symptoms also impact many facets of patient’s lives. They include disruptions in the sleep-
wake cycle, mood fluctuations, and abnormalities with the sensory nervous system.6 Sleep 
difficulties have been reported in 60-98% of PD patients as side effects of medications or 
intrinsic to the course of the disease.8 PD also affects the circadian rhythm by making 
patients more likely to nap during the day, which causes more wakefulness during 
nighttime hours.7 In addition to sleep, lost sense of smell often appears before the first signs 
of motor symptoms.8 Nearly 90% of PD patients experience olfaction deficits before 
diagnosis.9,10 As a result, sense of smell is used as an early predictor of developing the 
illness. 
In addition to these non-motor symptoms, PD can also impact the cognitive 
functioning of patients. PD patients have a 6-fold increase in dementia risk relative to their 
peers.11,12 Analyzed another way, the prevalence of dementia across a cohort of PD patients 
is approximately 31%.13 The prevalence of dementia also markedly increased with age 
whereby older PD patients demonstrating a 12-fold increase in risk when compared to 
younger patients.14 Dementia typically presents with a range of symptoms including 
memory loss, language and communication difficulties, troubles with information 
processing, and visual perception. However, PD patients generally exhibit slowed 
information processing rather than problems with memory or language.11 
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B. Discovery of Disease 
Research into Parkinson’s Disease has advanced significantly since its initial 
description in the 1800’s and has had several milestone discoveries over the past two 
centuries (Table 1). James Parkinson was the first to describe Parkinson’s Disease in his 
1817 essay titled “The Shaking Palsy.”15 It was the first report to describe the hallmark 
features of Parkinson’s Disease, such as tremors, rigidity, and bradykinesia. Over the 
following century, other studies described the disease in greater detail. Jean-Martin Charcot 
observed that PD developed first with either tremors or with rigidity, but that not all cases 
necessarily involved both symptoms.15 In effect, there were two different variations of the 
disease beginning with either symptom. These observations support the notion that not all 
cases of PD are identical and that several different clinical presentations can all result in a 
diagnosis of Parkinson’s Disease. 
In the 1800’s, little was known about the biochemical underpinnings of the disease. 
However, PD became first classified as a neurological disorder in the 1900’s. This 
classification began after Fritz Lewy discovered abnormal protein accumulations within 
the dorsal vagal nucleus that he identified in a 1913 publication.9 It was not until later that 
these abnormal accumulations were identified as Lewy Bodies (LB). These results 
prompted further research into the anatomical underpinnings of the disease. In 1925, 
Edouard Brissaud first proposed that the substantia nigra was the location where pathology 
began.15 The substantia nigra is located within the midbrain and is primarily responsible 
for movement.16 After identifying the location of pathology, efforts shifted towards 
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understanding what exactly causes the pathology. Over the next 50 years, research began 
on the genetic underpinnings of PD. 
 
Table 1. Overview of major findings in Parkinson’s Disease Research. 
Year Major Finding Citation 
1817 “Shaking Palsy” essay published by James Parkinson that first 
characterized major symptoms of PD 
  
Goetz, 2011 
1872 Jean-Martin Charcot described Parkinson’s as being initiated 
by two different mechanisms: rigidity and tremor 
  
Goetz, 2011 
1913 Fritz Lewy first identified protein accumulations that would 
later be called Lewy Bodies in the brain tissue of PD patients 
  
Greenfield, 
1953 
1925 First neural origins of the disease as pathology was 
hypothesized to begin in the substantia nigra 
  
Goetz, 2011 
2003 Staging system identified whereby PD theorized to spread from 
brainstem to outer cortex 
  
Braak, 2003 
 
 
C. Current Understanding of Disease Pathogenesis 
Parkinson’s disease has largely been identified as a disease of dopaminergic 
neurons of the substantia nigra, pars compacta.17 By the time of death, a Parkinson’s 
Disease patient can lose up to 70% of their dopaminergic neurons within the pars 
compacta.18 Well the process of dopaminergic neuron death is still incompletely 
understood, it has been shown that neurons undergo death by both apoptosis and 
autophagy.19 In more recent years, additional factors such as neuroinflammation have been 
shown to contribute to this process of neuronal death.20 With the death of these neurons, 
dopamine (DA) output expectantly begins to decline. As these dopaminergic neurons 
project onto the basal ganglia, the predominant brain structure responsible for movement, 
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motor function is impaired due to the reduced DA amounts. With the reduced concentration 
of neurons, the delicate balance within this pathway becomes imbalanced and the motor 
symptoms of Parkinson’s disease are observed. 
D. Familial vs. Sporadic Parkinson’s 
 PD pathogenesis can be classified into two main categories: familial and sporadic. 
Sporadic PD is responsible for 85% of cases and develops with no known genetic 
underpinnings. Contrarily, familial PD composes the remaining 10-15% of cases.21,22 The 
first gene identified in this familial form of PD was in SNCA, a gene that codes for α-
synuclein (α-SN), a monomeric protein located mainly within the brain.23 The mutation in 
SNCA is characterized by changing an adenine residue to a thymine residue at the 53rd 
position (A53T), causing the synuclein protein to change its conformation into fibrils.24 
Importantly, this mutation has not been found in cases of sporadic PD, further supporting 
the notion that there is a delineation in PD pathogenesis between familial and sporadic 
development. Since the identification of this SNCA mutation, several more genes have been 
identified as associated with familial PD such as LRRK2, PINK1, and PARK7 (Table 
2).25,26,27 
 The genetic underpinnings of familial PD are more thoroughly understood, 
meaning that the currently understood mechanisms behind pathogenesis are better defined. 
As a result, this thesis will discuss PD pathogenesis from the perspective of a familial 
inheritance pattern. However, it is important to note that the sporadic form of Parkinson’s 
disease could still follow a similar mode of pathogenesis. Sporadic PD might still have 
some of the genetic mutations observed in familial PD or it might present with entirely new 
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genetic mutations. Less is known about sporadic PD at this time, making it more difficult 
to concretely discuss the mode of PD pathogenesis. 
Table 2. Genetic mutations associated with Familial Parkinson’s Disease. 
Year Locus Gene Citation 
1997 PARK1 SNCA Polymeropoulos et al., 1997 
2001 PARK6 PINK1 Valente et al., 2001 
2003 PARK7  PARK7 Bonifati et al., 2003 
2004 PARK8  LRRK2 Zimprich et al., 2004 
 
E. Role of α-synuclein 
While the function of (α-SN) has not been fully defined, the location is relatively 
well understood. α-SN is mainly located within the presynaptic nerve terminal, but 
expression is also elevated within the intestinal tract, bone marrow, and endometrium.28,29 
Within the neuron, it has been suggested that α-SN is involved with maintaining a constant 
pool of vesicles in the presynaptic terminal.30 Specifically, it achieves this function through 
interactions with SNARE proteins, which are specialized proteins within the presynaptic 
neuron that assist with vesicular fusion to the plasma membrane. α-SN is a chaperone 
protein that assists with the folding of SNARE proteins.31 
α -synuclein has been extensively studied due to its hypothesized connection to PD. 
As referenced earlier, the neuronal accumulations known as Lewy Bodies appear to be a 
hallmark of PD. Lewy Body samples from the brain tissue of PD patients are predominantly 
composed of the α-SN protein.32 The overwhelming presence of α-SN within these 
inclusions raises the question of what causes this pathology to occur. The widely accepted 
hypothesis is that α-SN adopts misfolded conformations, which causes the proteins to 
clump together in Lewy Bodies and lose their endogenous function (Figure 1). Moreover, 
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research demonstrates that Lewy Bodies were found in 95% of PD patients, and that Lewy 
Body quantities are related to the severity of cognitive impairment.33 Based on the 
connection of α-SN to Lewy Bodies, and the connection of Lewy Bodies to PD, researchers 
have naturally focused their efforts on understanding what causes α-SN to become 
pathogenic. 
 
  
Figure 1. Immunohistochemistry staining of antibodies against α-SN. Image illustrates 
α-SN deposits within the substantia nigra of a PD patient. α-SN becomes misfolded and 
aggregates together as Lewy Bodies. Adapted from (Spillantini et al., 1998).32 
 
Braak and colleagues investigated this connection further and observed a 
systematic pattern of α-SN accumulation within the brain.34 Specifically, they observed 
that α-SN appeared confined to the brainstem of PD patients at the beginning of the disease. 
As the disease progressed, α-SN density was found to spread upwards through the 
brainstem and outwards around the cortex (Figure 2). As the pathology progressed, Lewy 
Bodies did not move away from the brainstem, but instead continually increased in density 
while also spreading to the other brain regions. Based on this observation, Braak and 
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colleagues proposed a 6-stage system whereby the location and density of α-SN aggregates 
can be related to the severity of the disease. 
 
Figure 2. Mechanism of rostral spreading of PD pathology within the brainstem. 
Proposed 6-stages of PD spreading from the olfactory bulb at stage 1 to the neocortex in 
stage 6. While pathology is spreading rostrally, the severity of the lesions at each of the 
previous stages increases. This increase in severity is shown by the darker shading. 
Adapted from (Braak et al., 2003).35 
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Additionally, one of the current debates in the literature remains hinged around 
whether α-SN causes PD through toxicity associated with Lewy Body clumps, or the loss 
of function associated with losing functional α-SN protein.36 While the presence of LB 
aggregates is associated with Parkinson’s disease, the mechanism whereby these LBs cause 
pathology is still incompletely understood. One of the largest challenges facing Parkinson’s 
research is determining how exactly the presence of these LB aggregates leads to 
Parkinson’s disease. Making this problem more challenging, research has still not 
determined whether the pathology is caused by the presence of LB aggregates or from the 
loss of function associated with losing healthy α-SN into the misfolded form. Furthermore, 
it is difficult to even determine whether losing healthy α-SN protein would have a 
detrimental effect because its endogenous function is still somewhat a mystery. The normal 
function of α-SN must be fully understood before we can discover the effect of losing 
healthy α-SN. As discussed, it has only been demonstrated that the protein assists with 
ensuring a constant supply of vesicles at the presynaptic terminal. However, applying this 
known function to understanding Parkinson’s Disease pathogenesis is currently a mystery. 
While it has been established that several mutations affect the normal functioning 
of α-SN and cause it to adopt a fibrillar conformation, it still remains to be determined how 
this misfolding results in the Lewy Body aggregates. One of the leading theories postulates 
that α-SN functions in a prion-like mechanism.37 Prions are a specific class of proteins that 
become misfolded and serve as a template for other proteins to adopt the same misfolded 
conformation. This misfolding propagates until large fibrillar clumps can be found in the 
particular target tissue. Assuming this model, misfolded α-SN serves as a template for 
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healthy α-SN to become misfolded and ultimately form into LB aggregates. As implied by 
the name, α-SN normally adopts an alpha helical configuration under its endogenous state. 
Once pathology begins, it has been shown to adopt a beta-pleated sheet orientation.38 These 
beta-sheets layer together and form the large insoluble fibrils that cause other healthy α-
SN to adopt the fibrillar conformation (Figure 3). 
Evidence of this hypothesis has been demonstrated by experimentally injecting 
mice with LBs and observing the result. When purified LB extracts from postmortem 
human PD patients are injected directly above the substantia nigra of mice, their 
dopaminergic neurons showed signs of degeneration with an associated increase in PD-
like symptoms.39 As discussed before, there is debate whether PD pathology stems from 
toxicity associated with LBs or from a loss of function from losing healthy α-SN. These 
data support the notion that LBs are toxic when situated within the substantia nigra since 
these mice still expressed their native healthy α-SN. 
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Figure 3. Structural representation of α-SN fibril. (a) Central portion of α-SN monomer 
in fibrillar conformation. (b) Layering and alignments of α-SN monomers. (c) Beta sheet 
alignment of the central α-SN monomer with side chains. Adapted from (Tuttle et al., 
2016).38 
 
F. Gut-Brain Hypothesis 
While the prion hypothesis of α-SN propagation provides an explanation of how 
the protein becomes misfolded, it still needs to be explained why Lewy Bodies appear in 
the brain rather than in other tissues. As mentioned before, α-SN is expressed in the bone 
marrow, endometrium, and GI tract, in addition to the brain, so research must identify why 
α-SN pathology is only associated with the brain rather than other tissues. One of these 
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proposed mechanisms whereby α-SN pathology appears within the brain is the gut-brain 
axis. Heiko Braak was the pioneer of this hypothesis based on the relationship between the 
gut, the vagus nerve, and the brainstem.35 The enteric nervous system connects to the brain 
through the vagus nerve and is associated with the brainstem at the dorsal motor nucleus 
of the vagus nerve (DMV). Since the DMV is one of the locations where Braak found the 
initial signs of PD pathology, this led to the theory that PD pathogenesis actually began 
within the gut.17 Braak and colleagues postulated that an unknown pathogen could gain 
access to the enteric neurons and cause the locally expressed α-SN to misfold and travel 
upwards through the vagus nerve in a prion-like mechanism.34,35 Once the misfolded α-SN 
reaches the DMV, the pathology can spread rostrally according to the Braak staging 
scheme. 
More recent findings have strengthened this initial theory. Nine out of 10 PD 
patients demonstrated α-SN deposits within the lamina propria of the colon, suggesting that 
there could be a potential correlation between GI α-SN and PD development.40 
Additionally, α-SN injections into the gut of adult rats produce a time-dependent increase 
in α-SN within the vagus nerve, consistent with a prion-like propagation of α-SN.36 While 
this association has been demonstrated, thus far there has been little research describing 
the mechanism whereby α-SN might move throughout the vagus nerve. Instead, some 
research has attempted to provide potential theories of this mechanism. To move between 
neurons, one research article hypothesizes that misfolded α-SN would need to exit one 
vagal neuron through exocytosis and enter the extracellular space.41 Once in the 
extracellular space, it would need to be taken up through endocytosis by an adjacent vagal 
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neuron where it could then induce pathology within that neuron (Figure 4). This process 
of exocytosis and endocytosis would likely occur sequentially and in an upwards direction 
towards the brainstem in order to initiate pathology within the brain. While this hypothesis 
has some theoretical validity, there lacks any data to support this claim. Discovering this 
mechanism is an area where research is actively needed. 
 
 
Figure 4: Proposed model for α-SN propagation along vagus nerve. Misfolded α-SN 
gets released from a neuron and gains access to the extracellular space. From here, this 
misfolded α-SN can enter a new neuron and initiate pathology in a prion-like mechanism. 
This process repeats until the vagus nerve becomes occupied by this α-SN pathology and 
until it ultimately reaches the brainstem. Adapted from (George et al., 2013).41 
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While it has been shown that α-SN deposits are present in the digestive tract of PD 
patients and that these deposits travel up the vagus nerve, research has attempted to 
understand the qualities of this unknown pathogen. While this pathogen was initially 
completely unknown, supporting evidence has come in recent years from epidemiological 
research into cigarette smoking patients. Current and former smokers demonstrate a 
reduced risk of developing Parkinson’s disease.42 Furthermore, this association was 
strengthened by showing that smokers who used a greater number of cigarettes were less 
likely to develop PD.43 These patients are inhaling many substances through the cigarette 
smoke that would be potentially toxic to living organisms. Since smoking cigarettes serves 
as a protective factor against PD development, it was proposed that this unknown pathogen 
could be a living organism. In essence, the toxins in cigarette smoke could be toxic to the 
living pathogen and prevent it from causing α-SN pathology, thus resulting in the protective 
effects against PD. 
G. Intestinal Cells and α-SN Expression 
As illustrated earlier, the gut-brain axis suggests that misfolded α-SN gains access 
to the vagus nerve and travels towards the brainstem. While it was discussed earlier that 
the potential pathogenic substance gains access to the enteric nervous system through the 
walls of the gut, there are specific properties of the intestinal cells that allow this proposed 
pathway. The gut epithelium contains a variety of different cell types including Paneth 
cells, enterocytes, enteroendocrine cells (EEC), and goblet cells.44 Each cell type has an 
independent and important function in digestion, but the EEC cell is perhaps the most 
important to the gut-brain axis hypothesis. EEC cells are connected to the nerve fibers of 
 15 
the enteric nervous system at their basal lamina (Figure 5).45 These nerve fibers travel from 
the EECs through the myenteric plexus and connect to the vagus nerve.  
 
 
Figure 5. Cross section of duodenal villi showing α-SN expression. Top panel: Enteric 
nerves innervate the regions between villi. α-SN (red) is shown within these enteric nerves. 
A cholecystokinin (CCK) cell (green) is shown enlarged in the image on the right. α-SN is 
found in large quantities near to these cells. Enteric nerves are located near the CCK cells. 
Bottom panel: PYY cell (green) located in close proximity to an α-SN stained nerve within 
the lamina propria. Adapted from (Chandra et al., 2017).46 
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Interestingly, the α-SN protein is expressed in these EEC and PYY cells (Figure 
5).46 Thus, the EEC could provide an optimal bridge between the gut and the nervous 
system for this infectious substance to propagate. According to the gut-brain axis 
hypothesis, the pathogen could gain entry inside or near the EEC and cause the natively 
expressed α-SN to misfold. After the protein misfolds, it could gain access to the nerves of 
the myenteric plexus. Intestinal cells have been demonstrated to exhibit fibrous-like 
projections from their basolateral surface that make direct contact with enteric nerves 
(Figure 6).46 This connection provides a direct pathway for misfolded α-SN to be 
transmitted from the EEC to the nerve. Alternatively, α-SN could leave the intestinal cells 
by exocytosis and subsequently be taken up by the enteric neurons through endocytosis in 
a more indirect pathway.46 
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Figure 6. Fibrous-like projections from intestinal cell to vagus nerve. Intestinal cells 
shown alongside enteric nerve (PGP9.5, red). α-SN positive cell (green) possesses fibrous-
like projections that encircle the enteric nerve, providing a direct pathway for α-SN to be 
transmitted to nerve. Adapted from (Chandra et al., 2017)46 
 
H. Intestinal Permeability 
 Another hallmark of the gut-brain axis is increased intestinal permeability. With a 
more permeable GI tract, more opportunities are available for foreign objects and potential 
pathogens to gain access to the underlying mucosa. Thus, research has attempted to 
investigate the connection between intestinal permeability and PD. In an experiment that 
administered oral sucralose to both PD patients and controls, urinary sucralose 
concentration was significantly higher in PD patients.47 This higher urinary concentration 
implies that more sucralose exited the GI tract lumen due to an increased permeability. 
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Additionally, the same study also discovered that PD patients had higher amounts of E. 
coli as well as LPS endotoxin within their intestinal wall. While the E. coli or LPS might 
not be serving as the unknown pathogenic agent causing α-SN pathology, their presence 
within the intestinal mucosa illustrates that other possible pathogenic agents of similar size 
to E. coli could also gain access to the mucosa and cause pathology. 
One of the potential factors possibly leading to this increased intestinal permeability 
is chronic psychological stress.48 Continual psychological stress releases the body’s 
endogenous stress hormone, cortisol. Interestingly, cortisol levels have been associated 
with a reduced number of tight junction proteins between epithelial cells in the colon of 
rats.48 By reducing the abundance of tight junction proteins, the gaps between intestinal 
epithelial cells are widened, allowing bacteria, pathogens, and other smaller foreign 
substances to gain access to the mucosa. This increase in permeability was confirmed by 
perfusion experiments with the colons of psychologically stressed rats that showed an 
increase in the intestinal permeability to radiolabeled Polyethylene Glycol 400.48 
I. Current Therapies and Need for New Advancements 
Much as our understanding of Parkinson’s disease has evolved over the past couple of 
centuries, treatments have also continually advanced. While these treatments have been 
capable of addressing physical and cognitive symptoms of the disease, there is still no cure 
for the underlying cause. For example, there are treatments for PD symptoms of depression, 
anxiety, cognitive dysfunction and motor functions, but no ultimate cure.49,50 The following 
section will describe four of the main treatments including levodopa, surgical procedures, 
Monoamine oxidase B (MAO-B) and Catechol-O-methyltransferase (COMT) inhibitors, 
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and immunotherapy. This passage will also discuss the need for new advancements in 
treatment that the gut-brain axis hypothesis can hopefully help address. 
1. Levodopa (L-DOPA) 
The most widely adopted therapy for PD is Levodopa (L-DOPA), which was 
discovered as a groundbreaking therapy in the late 1960’s when the drug caused noticeable 
and sometimes lifesaving improvements in PD patients.50 L-DOPA serves as the biological 
precursor to DA and undergoes a conversion through the enzyme dopa carboxylase to 
produce DA. As a result, L-DOPA functions to partially restore DA concentrations within 
the substantia nigra. In a randominzed, double-blind, placebo-controlled study with 361 
participants, L-DOPA was found to significantly reduce the worsening of PD symptoms in 
a dose-dependent manner.51 This data suggests that L-DOPA can help slow the progression 
of the illness, but cannot stop or reverse the course of Parkinson’s disease. Since the 
mechanism of L-DOPA only helps to restore the depleted DA levels, it does not target the 
underlying reason for dopaminergic neuron death. 
Furthermore, L-DOPA therapy has well described side effects and difficulties with the 
dosing schedule. One of the first described side-effects of long-term L-DOPA usage was 
something termed “start hesitation” by Ambani and Van Woert.52 They found that PD 
patients taking L-DOPA for periods of longer than 2 years experienced difficulty with 
initiating movement that was functionally different from PD patients without L-DOPA 
therapy. Building upon these side effects, further research classified this as an “on-off” 
phenomenon, which is defined as the fluctuation in motor capabilities in PD patients taking 
L-DOPA medication (Figure 7).53 Long-term PD patients frequently cycle through the 
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“off” period as a dose of L-DOPA medication wears off. Part of this phenomenon is related 
to naturally decreasing L-DOPA plasma concentrations due to the medication’s half-life, 
but part of this phenomenon could be explained by alternative means relating to absorption. 
Nutt and colleagues attributed a possible cause of these fluctuations to differences in 
absorbance between patients.53 Patients taking L-DOPA on a fasted stomach reached peak 
plasma levels more quickly, while patients taking L-DOPA after a meal had delayed 
absorption.53 This suggests that the pharmacokinetics of L-DOPA are dependent on 
absorption, which could be helping to exaggerate this “on-off” phenomenon of the drug’s 
effectiveness. 
 
Figure 7. Motor fluctuations in PD patients with L-DOPA therapy. Bottom panel 
illustrates plasma L-DOPA concentrations with repeated oral administration throughout 
the day. Upper panels demonstrate fluctuation in physical symptoms that coincide with L-
DOPA administration (Adapted from Nutt et al., 1984).53 
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2. Surgical Procedures 
Deep Brain Stimulation (DBS) is a surgical treatment developed for more advanced 
cases of Parkinson’s disease and involves the placement of an electrode within the 
subthalamic nucleus to stimulate this region with electrical activity.54 This treatment was 
designed as an alternative to patients after using L-DOPA for prolonged periods of time. 
DBS helps to reduce the “off” periods associated with long-term L-DOPA therapy and 
maximizes the “on” periods. In effect, the goal of DBS is to smoothen out daily highs and 
lows of L-DOPA efficacy so that PD patients can live more predictable and comfortable 
lives. 
In a small trial of 20 PD patients, DBS improved motor functioning in the “off” 
medication periods at 1, 3, 6, and 12 months after surgery.54 Patients in this trial found that 
they did not experience the same drop in motor functions normally experienced between 
doses of L-DOPA. Strengthening upon these findings, a randomized control trial for deep 
brain stimulation (DBS) with 156 PD patients was shown to improve a variety of metrics 
including mobility and emotional well-being.55 Specifically, this research group measured 
motor symptoms on the UPDRS-III scale where lower scores are indicative of fewer motor 
symptoms. PD patients in the L-DOPA + DBS group improved their UPDRS-III scores 
from 48.0±12.3 to 28.3±14.7. Meanwhile, UPDRS-III scores only improved from 18.9±9.3 
to 14.6±8.5 with regular L-DOPA medication alone. Furthermore, well-being was 
measured using the PDQ-39 assessment where lower scores indicate a better quality of life. 
Predictably, the DBS group of patients had a PDQ-39 score improvement from 41.8±13.9 
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to 31.8±16.3. Collectively then, these results demonstrate a clear and impactful 
improvement of DBS + L-DOPA therapy when compared to only L-DOPA administration. 
3. MAO-B and COMT Inhibitors 
MAO-B and COMT are two enzymes responsible for the degradation of L-DOPA.56 In 
the case of COMT, PD patients with high COMT activity demonstrated more rapid 
cognitive decline, suggesting that inhibiting this enzyme could help slow the decline.57 
Research into rat models has revealed that administration of entacapone, a COMT inhibitor 
medication, increased turning behavior, which is a proxy for motor functioning.58 This 
research further found that treatment with entacapone increased extracellular levels of DA. 
Entacapone has also been successful in human populations. In a randomized placebo 
double-blind study, entacapone decreased the “off” period associated with L-DOPA 
therapy and also allowed patients to lower their L-DOPA dose by 54mg.59 This reduction 
in L-DOPA dosage represented a 9.1% reduction, which could provide significant benefits 
by reducing drug resistance and long-term side effects.  
The two main MAO-B inhibitors are selegiline and rasagiline, although rasagiline has 
become more prevalent recently because of the toxic side effects that are associated with 
selegiline.60 Interestingly, a 3-year retrospective study comparing the differences between 
selegiline and rasagiline showed that both drugs were equally effective in controlling both 
motor and non-motor symptoms.61 Furthermore, the same research also identified a 
reduction in L-DOPA dosage of 75mg for selegiline patients and 106mg for rasagiline 
patients. Collectively then, both COMT and MAO-B inhibitors assist with symptoms of 
Parkinson’s disease and reduce the required L-DOPA dosage.  
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4. Attempts at Targeting Underlying Cause 
L-DOPA, DBS, and MAO-B and COMT inhibitors are excellent for treating symptoms 
of PD and delaying its progression, but they do not target the underlying reason behind PD 
development. An ultimate cure to the disease cannot be found if no treatments target the 
mechanism of pathogenesis. As referenced earlier, one prevailing theory for PD is that α-
SN misfolds, then gains entry to the extracellular space and continues propagating the 
pathology in a prion-like mechanism. As a result, certain immunotherapies have attempted 
to bind α-SN within the extracellular space and remove it from the brain.62,63 Mice 
immunized with human α-SN produce antibodies against their own endogenous α-SN.62 
These immunizations ultimately resulted in lower amounts of α-SN accumulation in the 
temporal cortex.62 This immunization treatment ultimately protected against neuronal cell 
death such that neuron concentration levels were near that of healthy controls. Building 
upon these results, a separate study demonstrated that α-SN overexpressing (ASO) mice 
immunized with monoclonal antibodies against α-SN showed improved motor and 
memory function.63 This research added that α-SN antibodies reduced the propagation of 
α-SN between cells.  
Collectively, this research in mouse populations provides promise for the application 
of immunotherapy to human PD patients. Presently, one phase I clinical trial has been 
conducted to evaluate the safety of a humanized monoclonal antibody termed PRX002.64 
Results showed that patients generally had few harmful side effects and that serum α-SN 
concentrations were drastically reduced in a dose-dependent manner, suggesting that the 
antibody was indeed effective. However, further research into the PRX002 antibody must 
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determine whether it is binding α-SN systemically or specifically within the brain. This 
antibody can only be an effective treatment if binding occurs within the brain and reduces 
the cell-to-cell transfer of α-SN. 
 While immunotherapy provides some promise as a potential treatment targeting the 
underlying PD mechanism, there is still much work to be conducted before proving its 
efficacy in humans. Furthermore, immunotherapy still only targets the pathogenesis of the 
disease after it has begun. The most promising treatments towards finding a cure will target 
α-SN before it misfolds and accumulates as LBs within the brain. The gut-brain axis 
hypothesis offers this exact possibility to stop the pathology before Parkinson’s disease 
begins. As a result, treatments can hopefully either prevent α-SN from misfolding or stop 
misfolded α-SN from reaching the brain. Once misfolded α-SN reaches the brain and cause 
dopaminergic neuron death, treating the illness becomes immeasurably more difficult.  
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SPECIFIC AIMS 
 
Specific aims of the following thesis include: 
1. Providing a thorough summary of the current literature surrounding the gut-brain 
axis hypothesis of PD. 
2. Present and evaluate the possible unknown pathogens contributing to α-SN 
pathology. 
3. Analyze the currently proposed therapies for PD based on the mechanism of the 
gut-brain axis hypothesis. 
4. Comment on the future directions that research must take to resolve some of the 
current disputes in the literature.  
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II. DISCUSSION 
 
 The gut-brain axis hypothesis has emerged as a plausible and credible method of 
how Parkinson’s Disease begins. This hypothesis has stemmed from decades of research 
into the connection between the enteric nervous system and the brainstem through the 
vagus nerve and how this could provide a potential pathway for α-SN transport. The 
purpose of this discussion will be to present the possible pathogens, evaluate the effect of 
diet over gut microbiota composition, examine the currently known mechanism of α-SN 
translocation and transport through the vagus nerve, and analyze what can be learned from 
research into vagotomy procedures. Through this evaluation, this thesis hopes to provide 
more clarity on the current climate of gut-brain axis research as it relates to PD. 
A. Possible Pathogens 
One of the core postulates behind the gut-brain axis hypothesis is the presence of 
an unknown pathogenic entity that can gain access to the gut wall. As discussed earlier, 
several different types of bacteria have altered levels in PD patients, which could be 
causing this pathogenic activity (Table 3). However, research findings have also pointed 
to the role of oxidative stress on protein folding and the possibility that this could be 
causing the pathogenic activity. Any of these potential mechanisms could be involved in 
α-SN pathology, but the challenge remains to identify the correct entity actually causing 
the damage. The following section will discuss the arguments presented for each possible 
pathogenic mechanism. 
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Table 3. Possible pathogens causing α-SN pathology. 
Citation Pathogen Key Findings 
Berstad, 
2017 
Actinobacteria Actinobacteria spores allow for a long latent 
period before disease onset 
  
Shen, 2017 Helicobacter pylori PD incidence was 1.59 times higher in H. 
pylori-infected populations 
  
Scheperjans, 
2015 
Prevotella and 
Enterobacteriaceae 
Bacteria positively associated with postural 
instability and gait difficulty 
 
 
1. Actinobacteria 
One of the most characteristic aspects of PD is its long latency period. Although 
there are certain rare forms of PD that can develop in younger populations, the disease 
primarily occurs in older individuals. This heavy age-dependent increase in PD incidence 
suggests that the pathogenic mechanism must remain dormant throughout the younger 
years of life and only appear as patients age. 
Actinobacteria, a class of gram-positive spore-producing bacteria, have been 
proposed as the infectious agent capable of demonstrating this age-dependent increase in 
PD incidence.65 This class of bacteria reproduce by creating spores, which can remain 
dormant for prolonged periods of time. These spores can then be seeded within the gut 
throughout the lifetime and cause α-SN pathology later in life when they develop into 
mature Actinobacteria. Researchers have termed this the “hibernating spore hypothesis.”65 
Actinobacteria spores are normally degraded by macroautophagy, a normal bodily 
process whereby cellular components become degraded within the lysosome.65 Under 
homeostatic conditions, the macroautophagy system is effective in degrading and 
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removing these spores. However, these degradative mechanisms can become inhibited with 
certain gene mutations associated with PD. For example, the LRRK2 gene mutation inhibits 
the macroautophagy system of familial PD patients.66 However, researchers have also 
attempted to understand how the hibernating spore hypothesis could apply to cases of 
sporadic PD.  A current hypothesis to answer the sporadic portion is that macroautophagy 
could also decline as a natural process of aging, even without the LRRK2 gene mutation.65 
Thus, under both familial and sporadic mechanisms, an impaired macroautophagy system 
would allow the spores could accumulate in PD patients and develop into the mature 
Actinobacteria that might be causing α-SN pathology. However, the exact mechanism 
whereby Actinobacteria could cause pathology is unknown and needs further exploration. 
Berstad and colleagues further explored the concept of the long latent period by 
arguing that viral and bacterial pathogens, except for Actinobacteria, would likely create a 
much more rapidly progressing pathology and cause PD to appear much earlier in life.65 
While this argument does support the concept of the hibernating spore hypothesis, their 
argument is not completely accurate. Many viral and bacterial pathogens other than 
Actinobacteria spores still have long latent periods, such as with HIV.67 After the initial 
HIV infection, it will take years before it develops into AIDS and allows opportunistic 
diseases to appear. Thus, while the hibernating spore hypothesis does have merits based on 
the dormant period of spores, it does not preclude other viral or bacterial agents from 
serving as the unknown pathogen. Actinobacteria and the hibernating spore hypothesis are 
one possibility for the unknown pathogen, but they are not the only possibility. 
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Moreover, the hibernating spore hypothesis has yet to receive data to quantitatively 
support its merits. At the moment, this hypothesis remains only a theory based on the 
thought that spores could accumulate within the GI tract and that Actinobacteria could be 
pathogenic to α-SN. At the present time, no research has characterized the accumulation of 
these spores within the GI tract of either humans or mice. Additionally, the mechanism 
whereby the mature Actinobacteria would cause damage to α-SN is unknown. Currently, 
it is only thought that Actinobacteria could secrete some endotoxin capable of misfolding 
α-SN, but this is only a speculative proposal. 
Finally, one of the largest pieces of evidence supporting the hibernating spore 
hypothesis is the fact that smokers have a lower prevalence of PD than non-smokers, as 
discussed earlier.42 This led researchers to postulate that the pathogen would likely be a 
living organism, leading to the idea of Actinobacteria. However, this relationship between 
smoking and PD prevalence has not been investigated in further depth. As PD is a disease 
that appears much later in life, it could be that smokers did not reach older ages due to 
deaths associated with their smoking habits. As such, the protective effects of smoking 
against PD could be nothing more than a correlation. More research must be conducted to 
specifically investigate the effects that cigarette smoke can have on the possible unknown 
pathogen before conclusions can be drawn. 
2. Helicobacter pylori 
Despite these arguments that bacterial species, other than Actinobacteria, could not 
be causing PD, there are other data that may implicate a particular strain of bacteria. 
Research dating back to the 1960’s has demonstrated a correlation with PD incidence and 
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stomach ulcers.68 Later research identified Helicobacter pylori as the unknown agent 
causing stomach ulcers.69 Predictably then, H. pylori infection was associated with a 1.59 
times greater risk of developing PD when compared to healthy controls.70 Moreover, H. 
pylori-infected PD patients demonstrated worse motor functions than PD patients without 
the infection.68 Interestingly, motor conditions improved in PD patients when H. pylori 
infections were eradicated.68 One possible cause of this relationship could be due to 
impaired medication absorption in infected patients. Principally, H. Pylori has been shown 
to decrease the absorption of L-DOPA.68 Expectantly then, treatment of H. pylori infections 
in PD patients was shown to improve the absorption of L-DOPA, which subsequently 
improves motor symptoms because more of the medication can be absorbed. This indicates 
that H. Pylori creates motor deficits through interference with medication, rather than being 
the root cause of α-SN pathology. Thus, while H. pylori has been proposed as the unknown 
pathogen, the evidence is suggestive that it does not cause α-SN pathology. 
3. Prevotella and Enterobacteriaceae 
Based on the idea that Actinobacteria, H. pylori, or E. coli could be causing pathology, 
the question is raised as to whether there are other bacterial species within the gut 
microbiota that might be influencing Parkinson’s pathogenesis. One study demonstrated 
that ASO germ-free (GF) mice displayed fewer α-SN inclusions and reduced motor deficit 
than control mice with a normal microbiota.71 This research further identified that treatment 
of ASO mice with antibiotics to limit microbial diversity also produced the same reduction 
of α-SN inclusions and motor deficits. Expectantly, ASO mice with a normal complement 
of microbiota demonstrated increased levels of α-SN inclusions and motor deficits.71 
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Collectively, this suggests that the presence of bacteria is required for PD pathogenesis to 
proceed. These findings indicate that either certain bacterial species are the unknown 
pathogen or that certain bacterial species are required to facilitate the function of another 
unknown pathogen. Either way, this provides strong evidence suggesting that the gut 
microbiota is involved in PD pathology. 
To investigate the identity of a bacterial species that could be the unknown pathogen, 
researchers sequenced the 16S ribosomal RNA genes of fecal samples from both PD and 
control patients.72 After sequencing, this research group discovered a higher proportion of 
Enterobacteriaceae and a lower proportion of Prevotella in PD patients when compared to 
healthy controls.72 This study further identified that a greater density of Enterobacteriaceae 
was positively correlated with postural instability and gait difficulty, both positive 
symptoms for PD. While these results provide initial evidence that both Prevotella and 
Enterobacteriaceae could be involved in PD pathogenesis, the challenge still remains in 
finding data that demonstrates causation rather than correlation. 
Continuing along this trend, bacteria from the genus Blautia, Coprococcus, and 
Roseburia were all found to be present in lower concentrations in PD patients than in 
healthy controls.73 Most importantly, these bacteria all produce butyrate, which is an anti-
inflammatory compound.73 This suggests that when these bacteria are present in lower 
numbers, less butyrate is produced, which in turn facilitates inflammation. As discussed 
earlier, inflammation can cause increased gut permeability through weakening the tight 
junctions, which would allow a potential opportunistic pathogen to target the α-SN in the 
intestinal mucosa. 
 32 
 
B. Potential Therapies 
Based on the evidence that bacteria are required for PD pathogenesis and that 
certain species are associated with positive PD symptoms, it raises the question of whether 
a potential therapy could revert these populations back to a normal composition. A 
healthier microbiome might prevent the colonization of this unknown pathogen and prevent 
pathology. Alterations in diet, supplementation, probiotic therapy, fecal microbiota 
transplants (FMT), and vagotomy procedures have all been proposed as potential therapies 
for PD based on the mechanism of the gut-brain axis hypothesis. 
1. Diet and the Microbiome 
A topic gaining increased attention in the scientific literature is the impact of our 
gut microbiota on health and disease. Not surprisingly, the microbiome has gained attention 
in relation to Parkinson’s disease after several research findings have shown that microbial 
dysregulation within our gut can be correlated to PD onset, as illustrated earlier in this 
thesis. This section will discuss how both supplementation with uridine and fish oils and 
modulating dairy intake could be promising for PD therapy. 
Evidence that gut bacteria maybe be involved in PD pathogenesis leads to the 
hypothesis that targeting bacteria may have therapeutic value. Perez-Pardo and colleagues 
have done research into the role of our diet on the gut microbiota and suggest that it could 
play a regulatory role in the gut-brain axis through changes in the gut microbiome.74 In one 
particularly influential study, it was demonstrated that uridine and fish oil diets could help 
alleviate PD motor symptoms in mice.75 Both uridine and omega-3 fatty acid 
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docosahexaenoic acid (DHA) are precursors for the phospholipids required to support 
healthy neuronal cell membranes.76 Since α-SN is also involved with vesicular docking to 
phospholipid membranes, there could be some interaction between α-SN and these 
supplements that alleviate the motor symptoms. This correlation is promising in the field 
of diet-based therapies for PD, but a defined mechanism must be first identified to clearly 
understand how uridine and DHA are exerting these effects. Perez-Pardo and colleagues 
further discovered that consuming a diet with uridine and DHA resulted in a reduction of 
α-SN accumulation within the gut. The authors suggested that this reduction could be due 
to a decrease in oxidative stress within the GI tract. The authors further referenced that 
oxidative stress might be responsible for increasing the intestinal permeability and allowing 
a pathogen to gain entry into the intestinal mucosa. By consuming a diet capable of 
reducing oxidative stress, fewer foreign particles could gain access and less α-SN 
accumulation could be observed as a result. 
Beyond the effect of uridine and fish oils, more common foods could be used in 
diet-based therapies. Interestingly, Chen and colleagues discovered that dairy products 
could place males at an increased risk for developing PD.77 More recent meta-analytic data 
bolsters these findings by suggesting that PD risk increased by 17% for every 200 g/day of 
milk consumption.78 Neither of these research articles identified the underlying cause for 
these findings or discussed their relation to the gut-brain axis. However, other research has 
demonstrated that consumption of dairy proteins has an effect on the gut microbial 
composition.79 This research article further concluded that dairy protein helped restore the 
gut microbiota to a more natural composition. This conclusion does not agree with the 
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previous research into the effects of the gut microbiota composition on PD. As described 
in this review, large amounts of research have identified that a disrupted gut microbiota 
composition is correlated with PD. However, this research did not include an analysis of 
the bacterial contents after milk protein consumption. It is possible that dairy products 
promote a healthy gut overall, but they alter the quantity of some bacteria species involved 
in PD. A more careful examination of the gut microbiota composition must be conducted 
to determine how milk influences PD pathogenesis. 
2. Probiotic Therapy 
Probiotic therapy has also been tested to treat PD disease symptoms.80,81 Probiotics 
are live microorganisms, such as bacteria, that are known to help digestion and the GI tract. 
Thus far, probiotic therapy has been successful in treating GI disorders of PD such as 
constipation and bloating.82,83 However, the ultimate goal is to treat the neurodegenerative 
symptoms that manifest as motor and cognitive difficulties. Some probiotic therapy has 
examined this prospect, which will be discussed below. 
There are anywhere between 300-500 different species of bacteria that compose 
our gut flora, and our understanding of how these species interact is still at its infancy.24 
As documented in several studies, PD has been shown to correlate with a relative change 
in gut bacterial content. At this time, we do not understand how a relative abundance or a 
relative decline of one bacterial population might have on the abundance or activity of 
other bacteria. Most research efforts have only shown correlations, but causal effects 
remain to be demonstrated. The lack of causal evidence is one of the largest problems 
facing diet or probiotic-based therapies today. Based on the current literature, we can only 
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conclude that some bacterial species might cooperatively or synergistically interact to 
affect the gut-brain axis. It is entirely possible that all the bacteria species mentioned above 
might create the optimal conditions for an unknown pathogen to gain entry to the intestinal 
mucosa and create α-SN pathology, rather than a bacterial species itself creating α-SN 
pathology. Additional research must be conducted before conclusions can be drawn. 
3. Fecal Microbial Transplantation 
FMT are another such treatment that could help change the GI bacterial 
composition. FMT is the process whereby stool samples from healthy donors are processed 
and administered to the colon of unhealthy recipients. The ultimate goal is to restore the 
recipient’s colon to a healthy composition of microbiota. This procedure has been 
implemented to assist with restoring a healthy gut flora in other disease models such as 
Clostridium difficile infections.84 Since gut microbiota has also been connected to 
pathogenesis in PD, it is logical that FMT therapy could also benefit PD patients. FMT 
could be given to a PD patient with microbial dysbiosis, allowing their microbiome to shift 
towards normal. With a more normal gut, there would be fewer harmful bacterial species 
that are potentially causing inflammation and α-SN pathology. This restoration to a normal 
microbial composition could then stop or at least slow the progression of pathogenesis 
through the gut. 
FMT has been researched in mouse models of PD as well as human PD patients, 
although little research has been conducted on the latter. Only a single case report has found 
an alleviation of some physical symptoms after FMT into a human PD patient.85 Mouse 
studies have been more convincing. FMT of a healthy microbiota into PD mouse models 
 36 
was shown to improve motor functions, increase dopamine concentration within the 
striatum, and partially rescued dopaminergic neurons from cell death.86 In one particularly 
influential experiment, ASO mice were given fecal samples from human PD patients with 
microbial dysbiosis.71 The ASO mice in this experiment were more susceptible to 
developing PD through the gut-brain axis because α-SN would be present in higher 
quantities within the gut. As a result, this would give the potential pathogen a greater 
chance of causing protein misfolding due to the greater abundance of α-SN. In this 
experiment, the genetically predisposed ASO mice developed motor impairments 
consistent with PD, while these results were not observed in healthy WT mice.71 These 
data help to determine that fecal samples from human PD patients can induce PD-like 
symptoms in healthy recipients. The next research step is to perform a FMT from a healthy 
donor and observe the effects on PD patients. Assuming this logic remains, we could expect 
PD patients to demonstrate a reduction or at least a pause in symptom progression with a 
FMT from healthy donors. 
4. Vagotomy Procedures 
One of the pillars of the gut-brain axis hypothesis of PD is the ability of α-SN to 
move along the vagus nerve. Logically, removing the vagus nerve via a vagotomy 
procedure could eliminate this pathway and prevent the spread of pathology. Several 
research groups have analyzed retrospective data to test this possibility. To understand this 
research, it is important to know the types of vagotomy procedures that can be conducted. 
Truncal vagotomies are the most extreme and involve a separation of the main trunk of the 
vagus nerve and result in denervation of the stomach, liver, pancreas, large bowel, and 
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small bowel (Figure 8). Alternatively, a selective vagotomy only severs the anterior or 
posterior gastric nerves, which are branches of the main trunk of the vagus nerve (Figure 
8). This leaves the main trunk of the vagus nerve intact, and still allows some contact of 
branching nerve fibers with the GI tract. Researchers predicted that α-SN pathology could 
not progress with truncal vagotomy procedures, but that it could progress with the selective 
vagotomies. However, the study of vagotomy patients has produced mixed results. 
 
 
Figure 8. Truncal vs. selective vagotomy procedure. Truncal vagotomy is categorized 
by severing the vagus nerve at the anterior trunk of the vagus nerve, while selective 
vagotomy is characterized by severing either the anterior or posterior gastric nerves, which 
are both branches of the anterior trunk of the vagus nerve (Adapted from Cooperman, 
1976).87 
 
Results from certain reports on vagotomy procedures validate the gut-brain axis, 
while other results provide contradictory evidence.88,89 Principally, these results depend on 
whether truncal and selective vagotomies are grouped together or are analyzed separately. 
In a grouped cohort of 9,430 patients who underwent either truncal or selective vagotomy 
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procedures, no protective effects are not observed (Hazard Ratio = 0.96).88 However, 
analyzing the subset of 3,445 patients receiving truncal vagotomy procedures from this 
cohort demonstrated a protective effect against developing PD at both 5-year (HR = 0.59) 
and 10-year (HR = 0.62) follow-ups (Figure 9).88 Building upon these results, Svensson 
and colleagues also observed a reduced risk of PD in truncal vagotomy patients when 
compared to the control population (HR = 0.84).89 This study also found that selective 
vagotomy procedures produced no measurable difference in PD incidence. 
Breen and colleagues investigated these results and explained the difference in PD 
incidence by the type of vagotomy.90 The vagus nerve is complex with several branching 
points, so when selective vagotomy procedures are conducted, there is still a large portion 
of the nerve left intact. Removing only a portion of this nerve will potentially still allow 
pathology to progress. When a complete truncal vagotomy is performed, there is no 
pathway for α-SN to travel upwards towards the brain because the nerve has been 
completely severed. When these vagotomy procedures are both included within the same 
cohort for analysis, it is possible that the protective effects of the truncal vagotomy are not 
strong enough to counteract the null effects of the selective vagotomy. 
However, strong conclusions still cannot be drawn from this research because this 
data was collected retrospectively. In any of these samples, it is possible that PD pathology 
began before the vagotomy procedure was conducted. In this sense, severing the vagus 
nerve would have no impact if pathology had already been initiated. Furthermore, the 
pathology could have begun within the brain, rather than the GI tract. If pathology began 
within the substantia nigra, a truncal or selective vagotomy should also have no effect on 
 39 
PD incidence since the GI tract is not involved. To determine this more experimentally, 
vagotomy procedures must be randomly assigned to populations of rats or mice and PD 
incidence must then be observed. Only experimental manipulation will indicate whether 
vagotomy procedures have an impact on PD pathology. 
 
 
  
Figure 9. Comparing truncal vs. selective vagotomy on PD incidence. Both truncal 
vagotomy and selective vagotomy were compared to their matched reference controls on 
the outcome variable of Parkinson’s disease incidence. Truncal vagotomy reduces PD 
incidence when compared to control populations, but selective vagotomy has no main 
effect. Adapted from (Liu et al., 2017).88 
 
Determining the impact of vagotomy procedures on PD pathogenesis is one of the 
most definitive experiments possible for evaluating the validity of the gut-brain axis. The 
entire premise behind this hypothesis is that α-SN travels along the vagus nerve into the 
brainstem, rather than through other routes such as the bloodstream or lymphatics. It is still 
possible that pathology could be initiating through alternative methods. As described 
above, the longstanding theory of PD pathogenesis is that LBs initiate within the brainstem 
and spread outwards from there. This mode of initiation could be explaining the mixed 
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results with vagotomy procedures. Assuming this method of pathogenesis is correct, 
pathology could begin with the brainstem, so it wouldn’t matter whether truncal or 
selective vagotomies were performed: they should both results in PD because they would 
have no relation to the mode of pathology. 
C. Mechanism of Pathogenesis 
While research has explored the correlations between bacteria and pathology, less 
information is available on how exactly this pathology occurs. Research demonstrates that 
α-SN is present within the vagus nerve of PD patients, but there is little information on 
how the α-SN actually gains entry and moves throughout the nerve. Does the misfolded α-
SN diffuse along the nerve according to a density gradient or does it attach to a substrate 
that physically carries the pathogenic protein? Alternatively, does α-SN propagate by 
systematically misfolding the adjacent α-SN proteins in a prion-like manner until this chain 
of misfolding proteins passes along to the next cell? Answering these questions would 
allow researchers to more accurately determine whether the gut-brain axis is a significant 
mode of PD pathogenesis. One of the principle reasons why this theory has not been 
unanimously adopted is the lack of a complete mechanism. Discovering a clear mechanism 
of pathogenic translocation into the mucosa, α-SN misfolding, entry into the vagus nerve, 
and travel along the vagus nerve would allow researchers to experimentally manipulate 
certain components and evaluate the gut-brain axis in greater detail. 
At the present moment, there are too many areas where alternative explanations 
could be made for the data. For example, the earlier presented data that certain bacterial 
species are correlated with an increased prevalence of PD development can be explained 
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through other means. The increased or decreased prevalence of certain bacterial species is 
not connected with a specific biological event, such as downregulation of tight junctions 
between epithelial cells or the translocation of a particular substance into the intestinal 
mucosa. At the moment, research has only identified that certain bacterial species are either 
increased or decreased in prevalence. Identifying the key biochemical factors that occur at 
each step of the pathway from a change within the gut to an increased translocation of 
misfolded α-SN into the vagus nerve is necessary. 
D. Reverse Travel of α-SN 
Most research on the gut-brain axis of PD pathogenesis assumes that misfolded α-
SN travels upwards along the vagus nerve and becomes deposited in the brainstem. 
However, other data does suggest that α-SN has the ability to travel downwards along the 
vagus nerve towards the gut.91 After injecting healthy rats with α-SN in the substantia nigra, 
Ulusoy and colleagues found a higher amount of α-SN expression within the myenteric 
plexus of the GI tract when compared to rats without substantia nigra injections.91 These 
results present an entirely new way of interpreting the gut-brain axis, one that almost 
entirely opposes the currently accepted theory. In summary, it has been demonstrated that 
injections of α-SN into the gut can lead to pathology within the brainstem, while injections 
within the brain can lead to α-SN accumulation within the gut. These two sets of data may 
seem to question the validity of the gut-brain axis hypothesis of PD. The challenge is that 
neither of these findings can be explained due to a lack of literature support. As referenced 
throughout this review, countless articles have demonstrated the accumulation of α-SN 
within the GI tract and the resultant outcomes on PD symptoms or pathology. Likewise, 
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there has been decades of research identifying the accumulation of LBs within the 
substantia nigra and surrounding brain regions of PD patients without any reference to 
accumulation with the GI tract. 
To resolve these conflicting ideas, it must first be determined whether these are 
indeed conflicting, or whether both mechanisms could serve a function in PD pathogenesis. 
Experiments could be conducted to pinpoint which comes first: α-SN accumulation in the 
gut or α-SN accumulation in the brain. This could be resolved by sampling a large cohort 
of samples both with and without PD and measuring α-SN pathology in both the gut and 
the brain. This would be possible in mice or rat populations experimentally, but this could 
only be conducted in post-mortem humans. As such, this data must be collected first in 
rodent samples. 
The research by Ulusoy and colleagues that describes the downward travel of α-SN 
does provide contradictory evidence for the gut-brain axis hypothesis, but it also deserves 
a closer analysis. Elements of this research are still consistent with the gut-brain hypothesis. 
In this research, α-SN was not detected within the vagus nerve of rats after 2 months and 
was only present in rats either 6-months or 12-months post-injection.91 The data followed 
a time-dependent increase such that the amount of α-SN present at 12-months was greater 
than at 6-months. This indicates that α-SN was not present within the vagus nerve initially, 
but that an abundance of α-SN within the substantia nigra somehow caused the 
accumulation within the vagus nerve over time. The fact that α-SN accumulates and moves 
through the vagus nerve in a slow and time-dependent fashion in the downward direction 
suggests that α-SN would also move slowly and in a time-dependent fashion in the upward 
 43 
direction from the gut. Instead, this time-dependent travel supports the idea that the 
pathology could begin within the gut many years before any pathology appears within the 
brain while the α-SN is moving in the upwards direction. 
Analyzing the data collectively, it seems possible that both directions of α-SN travel 
could be correct, and that PD pathology could arise from several different locations. All α-
SN pathologies eventually cause damage within the brain, but the initiation site could be 
different. In some variations of PD, pathology could begin directly within the brain, but it 
could begin within the GI tract in other variations and slowly travel upwards towards the 
brainstem.  
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III. CONCLUSION AND FUTURE DIRECTIONS 
The gut-brain axis hypothesis provides an interesting theory of PD pathogenesis 
and is one that deserves serious consideration. As demonstrated in this thesis, there is data 
that provides strong support for the hypothesis, but there are also results that cast some 
doubt on its validity. However, seeing as there is no current cure for Parkinson’s disease, 
every effort must be made to critically evaluate hypotheses that provide even small 
amounts of promise for an ultimate cure. In the process of evaluating the validity of the 
gut-brain axis hypothesis, it is important to understand that diseases such a Parkinson’s are 
multifaceted and likely have several different mechanisms of pathogenesis. As illustrated 
in this review, the gut-brain axis does hold validity to being at least one mechanism of PD 
pathogenesis, partly because there are so many ways that this hypothesis could be 
impacting PD pathogenesis. As demonstrated, there are different ways for intestinal 
permeability to increase and there are several different possible unknown pathogens. While 
specific mechanisms have not been determined, the current body of literature at least 
encourages further research to determine these potential mechanisms with further detail. 
Additionally, research can be directed towards more cumulative and holistic 
treatments of PD that take into account the gut-brain axis hypothesis. As mentioned in this 
thesis, current therapies revolve around L-DOPA, DBS, MAO-B and COMT inhibitors, 
and immunotherapy. These therapies all center around α-SN pathology within the brain 
after the disease has taken root. A positive step forward in research could combine these 
traditional treatments with some gut-brain axis specific treatments such as diet 
modifications, probiotic therapy, FMT, and vagotomy procedures. By providing a 
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collection of therapies to PD patients, we would hope to see additional improvements 
beyond just that of a single traditional therapy alone. 
Finally, the gut-brain axis has implications beyond Parkinson’s disease. The 
possibility that pathogens gain access to the body through the intestinal wall and create 
pathology could be important for other neurological diseases. Just as certain unknown 
pathogens could be gaining access and causing PD, other possible pathogens could be 
attacking the enteric nervous system helping to cause diseases such as Alzheimer’s. 
Research efforts on the gut-brain axis may lead to the discovery of novel mechanisms and 
therapies for any number of other diseases.  
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